{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:22:55Z","timestamp":1793812975441,"version":"4.6.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"DOI":"10.1038\/s43856-024-00700-x","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T07:38:56Z","timestamp":1734593936000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Computational assessment of measurable residual disease in acute myeloid leukemia using mixture models"],"prefix":"10.1038","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9170-4131","authenticated-orcid":false,"given":"Tim R.","family":"Mocking","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang\u00e8le","family":"Kelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1346-6606","authenticated-orcid":false,"given":"Tom","family":"Reuvekamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0969-3766","authenticated-orcid":false,"given":"Lok Lam","family":"Ngai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Rutten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrycja","family":"Gradowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjan A.","family":"van de Loosdrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Cloos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5983-6193","authenticated-orcid":false,"given":"Costa","family":"Bachas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"key":"700_CR1","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","volume":"6","author":"NJ Short","year":"2020","unstructured":"Short, N. J. et al. Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis. JAMA Oncol. 6, 1890\u20131899 (2020).","journal-title":"JAMA Oncol."},{"key":"700_CR2","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser, M. et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood 138, 2753\u20132767 (2021).","journal-title":"Blood"},{"key":"700_CR3","first-page":"3345","volume":"124","author":"D Grimwade","year":"2014","unstructured":"Grimwade, D. & Freeman, S. D. Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for \u201cprime time\u201d? Blood. J. Am. Soc. Hematol. 124, 3345\u20133355 (2014).","journal-title":"J. Am. Soc. Hematol."},{"key":"700_CR4","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.3390\/cancers14102537","volume":"14","author":"ME Salama","year":"2022","unstructured":"Salama, M. E. et al. Artificial intelligence enhances diagnostic flow cytometry workflow in the detection of minimal residual disease of chronic lymphocytic leukemia. Cancers 14, 2537 (2022).","journal-title":"Cancers"},{"key":"700_CR5","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/bjh.18802","volume":"202","author":"PC Nguyen","year":"2023","unstructured":"Nguyen, P. C. et al. Computational flow cytometry provides accurate assessment of measurable residual disease in chronic lymphocytic leukaemia. Br. J. Haematol. 202, 760\u2013770 (2023).","journal-title":"Br. J. Haematol."},{"key":"700_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14825","volume":"8","author":"E Arvaniti","year":"2017","unstructured":"Arvaniti, E. & Claassen, M. Sensitive detection of rare disease-associated cell subsets via representation learning. Nat. Commun. 8, 14825 (2017).","journal-title":"Nat. Commun."},{"key":"700_CR7","doi-asserted-by":"crossref","unstructured":"Verbeek, M. W. et al. Minimal residual disease assessment in B\u2010cell precursor acute lymphoblastic leukemia by semi\u2010automated identification of normal hematopoietic cells: a EuroFlow study. Cytometry Part B: Clin. Cytometry 106, 252\u2013263 (2023).","DOI":"10.1002\/cyto.b.22143"},{"key":"700_CR8","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/leu.2017.29","volume":"31","author":"J Flores-Montero","year":"2017","unstructured":"Flores-Montero, J. et al. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia 31, 2094\u20132103 (2017).","journal-title":"Leukemia"},{"key":"700_CR9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ebiom.2018.10.042","volume":"37","author":"B-S Ko","year":"2018","unstructured":"Ko, B.-S. et al. Clinically validated machine learning algorithm for detecting residual diseases with multicolor flow cytometry analysis in acute myeloid leukemia and myelodysplastic syndrome. EBioMedicine 37, 91\u2013100 (2018).","journal-title":"EBioMedicine"},{"key":"700_CR10","doi-asserted-by":"publisher","first-page":"71915","DOI":"10.18632\/oncotarget.12430","volume":"7","author":"W Ni","year":"2016","unstructured":"Ni, W. et al. Automated analysis of acute myeloid leukemia minimal residual disease using a support vector machine. Oncotarget 7, 71915 (2016).","journal-title":"Oncotarget"},{"key":"700_CR11","first-page":"1010","volume":"1012","author":"R Licandro","year":"2018","unstructured":"Licandro, R. et al. Application of machine learning for automatic MRD assessment in paediatric acute myeloid leukaemia. Cancer cells 1012, 1010 (2018).","journal-title":"Cancer cells"},{"key":"700_CR12","doi-asserted-by":"crossref","unstructured":"Licandro, R. et al. WGAN latent space embeddings for blast identification in childhood acute myeloid leukaemia. In 24th International Conference on Pattern Recognition (ICPR) 3868\u20133873 (ICPR, 2018).","DOI":"10.1109\/ICPR.2018.8546177"},{"key":"700_CR13","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1109\/TBME.2016.2590950","volume":"64","author":"B Rajwa","year":"2016","unstructured":"Rajwa, B., Wallace, P. K., Griffiths, E. A. & Dundar, M. Automated assessment of disease progression in acute myeloid leukemia by probabilistic analysis of flow cytometry data. IEEE Trans. Biomed. Eng. 64, 1089\u20131098 (2016).","journal-title":"IEEE Trans. Biomed. Eng."},{"key":"700_CR14","doi-asserted-by":"crossref","unstructured":"Weijler, L. et al. FATE: Feature-Agnostic Transformer-based Encoder for learning generalized embedding spaces in flow cytometry data. In Proceedings of the IEEE\/CVF Winter Conference on Applications of Computer Vision 7956\u20137964 (IEEE, 2024).","DOI":"10.1109\/WACV57701.2024.00777"},{"key":"700_CR15","doi-asserted-by":"crossref","unstructured":"Shopsowitz, K. et al. MAGIC-DR: An interpretable machine-learning guided approach for acute myeloid leukemia measurable residual disease analysis. Cytometry. Part B, Clin. Cytometry. 106, 239\u2013251 (2024).","DOI":"10.1002\/cyto.b.22168"},{"key":"700_CR16","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1200\/JCO.2012.45.9628","volume":"31","author":"M Terwijn","year":"2013","unstructured":"Terwijn, M. et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON\/SAKK AML 42A study. J. Clin. Oncol. 31, 3889\u20133897 (2013).","journal-title":"J. Clin. Oncol."},{"key":"700_CR17","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3390\/cancers13040629","volume":"13","author":"JP Vial","year":"2021","unstructured":"Vial, J. P. et al. Unsupervised flow cytometry analysis allows for an accurate identification of minimal residual disease assessment in acute myeloid leukemia. Cancers 13, 629 (2021).","journal-title":"Cancers"},{"key":"700_CR18","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1182\/blood-2019-129866","volume":"134","author":"V B\u00fccklein","year":"2019","unstructured":"B\u00fccklein, V. et al. Flowsom: an R-based evaluation strategy for flow cytometry-based Measurable Residual Disease (MRD) diagnostics in Acute Myeloid Leukemia (AML). Blood 134, 4656 (2019).","journal-title":"Blood"},{"key":"700_CR19","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1158\/1078-0432.CCR-22-2237","volume":"29","author":"A Canali","year":"2023","unstructured":"Canali, A. et al. Prognostic impact of unsupervised early assessment of bulk and leukemic stem cell measurable residual disease in acute myeloid leukemia. Clin. Cancer Res. 29, 134\u2013142 (2023).","journal-title":"Clin. Cancer Res."},{"key":"700_CR20","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3390\/diagnostics10050317","volume":"10","author":"H Jacqmin","year":"2020","unstructured":"Jacqmin, H. et al. Clustering and Kernel density estimation for assessment of measurable residual disease by flow cytometry. Diagnostics 10, 317 (2020).","journal-title":"Diagnostics"},{"key":"700_CR21","doi-asserted-by":"publisher","first-page":"898","DOI":"10.3390\/cancers14040898","volume":"14","author":"L Weijler","year":"2022","unstructured":"Weijler, L. et al. UMAP based anomaly detection for minimal residual disease quantification within acute myeloid leukemia. Cancers 14, 898 (2022).","journal-title":"Cancers"},{"key":"700_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1011288","volume":"19","author":"T Chari","year":"2023","unstructured":"Chari, T. & Pachter, L. The specious art of single-cell genomics. PLOS Comput. Biol.19, e1011288 (2023).","journal-title":"PLOS Comput. Biol."},{"key":"700_CR23","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.cels.2023.07.002","volume":"14","author":"S Wang","year":"2023","unstructured":"Wang, S., Sontag, E. D. & Lauffenburger, D. A. What cannot be seen correctly in 2D visualizations of single-cell \u2018omics data? Cell Syst. 14, 723\u2013731 (2023).","journal-title":"Cell Syst."},{"key":"700_CR24","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1182\/bloodadvances.2020003855","volume":"5","author":"B L\u00f6wenberg","year":"2021","unstructured":"L\u00f6wenberg, B. et al. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial. Blood Adv. 5, 1110\u20131121 (2021).","journal-title":"Blood Adv."},{"key":"700_CR25","doi-asserted-by":"crossref","unstructured":"Cloos, J. et al. Comprehensive protocol to sample and process bone marrow for measuring measurable residual disease and leukemic stem cells in acute myeloid leukemia. JoVE (Journal of Visualized Experiments), 133, e56386 (2018).","DOI":"10.3791\/56386-v"},{"key":"700_CR26","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.1002\/cpcy.66","volume":"91","author":"W Zeijlemaker","year":"2019","unstructured":"Zeijlemaker, W., Kelder, A., Cloos, J. & Schuurhuis, G. J. Immunophenotypic detection of measurable residual (stem cell) disease using LAIP approach in acute myeloid leukemia. Curr. Protoc. Cytometry 91, e66 (2019).","journal-title":"Curr. Protoc. Cytometry"},{"key":"700_CR27","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/cyto.a.23663","volume":"93","author":"G Finak","year":"2018","unstructured":"Finak, G., Jiang, W. & Gottardo, R. CytoML for cross\u2010platform cytometry data sharing. Cytometry Part A 93, 1189\u20131196 (2018).","journal-title":"Cytometry Part A"},{"key":"700_CR28","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/cyto.a.24501","volume":"101","author":"A Emmaneel","year":"2022","unstructured":"Emmaneel, A. et al. PeacoQC: Peak\u2010based selection of high quality cytometry data. Cytometry Part A 101, 325\u2013338 (2022).","journal-title":"Cytometry Part A"},{"key":"700_CR29","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/cyto.a.20258","volume":"69","author":"DR Parks","year":"2006","unstructured":"Parks, D. R., Roederer, M. & Moore, W. A. A new \u201cLogicle\u201d display method avoids deceptive effects of logarithmic scaling for low signals and compensated data. Cytometry Part A: J. Int. Soc. Anal. Cytol. 69, 541\u2013551 (2006).","journal-title":"Cytometry Part A: J. Int. Soc. Anal. Cytol."},{"key":"700_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2105-10-106","volume":"10","author":"F Hahne","year":"2009","unstructured":"Hahne, F. et al. flowCore: a Bioconductor package for high throughput flow cytometry. BMC Bioinform. 10, 1\u20138 (2009).","journal-title":"BMC Bioinform."},{"key":"700_CR31","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/cyto.a.22625","volume":"87","author":"S Van Gassen","year":"2015","unstructured":"Van Gassen, S. et al. FlowSOM: Using self\u2010organizing maps for visualization and interpretation of cytometry data. Cytometry Part A 87, 636\u2013645 (2015).","journal-title":"Cytometry Part A"},{"key":"700_CR32","doi-asserted-by":"publisher","first-page":"btae179","DOI":"10.1093\/bioinformatics\/btae179","volume":"40","author":"A Couckuyt","year":"2024","unstructured":"Couckuyt, A., Rombaut, B., Saeys, Y. & Van Gassen, S. Efficient cytometry analysis with FlowSOM in Python boosts interoperability with other single-cell tools. Bioinformatics 40, btae179 (2024).","journal-title":"Bioinformatics"},{"key":"700_CR33","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nmeth.3968","volume":"13","author":"J Lever","year":"2016","unstructured":"Lever, J., Krzywinski, M. & Altman, N. Points of significance: model selection and overfitting. Nat. Methods 13, 703\u2013705 (2016).","journal-title":"Nat. Methods"},{"key":"700_CR34","doi-asserted-by":"crossref","unstructured":"Fokken, H. et al. A 19\u2010color single\u2010tube full spectrum flow cytometry assay for the detection of measurable residual disease in acute myeloid leukemia. Cytometry Part A 105, 181\u2013195 (2023).","DOI":"10.1002\/cyto.a.24811"},{"key":"700_CR35","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.pathol.2019.09.021","volume":"52","author":"D Hanekamp","year":"2020","unstructured":"Hanekamp, D., Bachas, C., van de Loosdrecht, A., Ossenkoppele, G. & Cloos, J. Re: Myeloblasts in normal bone marrows expressing leukaemia-associated immunophenotypes. Pathology 52, 289\u2013291 (2020).","journal-title":"Pathology"},{"key":"700_CR36","doi-asserted-by":"publisher","first-page":"e1003130","DOI":"10.1371\/journal.pcbi.1003130","volume":"9","author":"A Cron","year":"2013","unstructured":"Cron, A. et al. Hierarchical modeling for rare event detection and cell subset alignment across flow cytometry samples. PLoS Comput. Biol. 9, e1003130 (2013).","journal-title":"PLoS Comput. Biol."},{"key":"700_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2022.105314","volume":"144","author":"M W\u00f6dlinger","year":"2022","unstructured":"W\u00f6dlinger, M. et al. Automated identification of cell populations in flow cytometry data with transformers. Comput. Biol. Med. 144, 105314 (2022).","journal-title":"Comput. Biol. Med."},{"key":"700_CR38","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1093\/biostatistics\/kxp062","volume":"11","author":"S Fr\u00fchwirth-Schnatter","year":"2010","unstructured":"Fr\u00fchwirth-Schnatter, S. & Pyne, S. Bayesian inference for finite mixtures of univariate and multivariate skew-normal and skew-t distributions. Biostatistics 11, 317\u2013336 (2010).","journal-title":"Biostatistics"},{"key":"700_CR39","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/cyto.a.24811","volume":"105","author":"H Fokken","year":"2024","unstructured":"Fokken, H. et al. A 19\u2010color single\u2010tube full spectrum flow cytometry assay for the detection of measurable residual disease in acute myeloid leukemia. Cytometry Part A 105, 181\u2013195 (2024).","journal-title":"Cytometry Part A"},{"key":"700_CR40","first-page":"1","volume":"18","author":"L Lin","year":"2017","unstructured":"Lin, L. & Li, J. Clustering with hidden Markov model on variable blocks. J. Mach. Learn. Res. 18, 1\u201349 (2017).","journal-title":"J. Mach. Learn. Res."},{"key":"700_CR41","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/cyto.b.22144","volume":"104","author":"JM Tettero","year":"2023","unstructured":"Tettero, J. M. et al. Analytical assay validation for acute myeloid leukemia measurable residual disease assessment by multiparametric flow cytometry. Cytometry Part B: Clin. Cytometry 104, 426\u2013439 (2023).","journal-title":"Cytometry Part B: Clin. Cytometry"},{"key":"700_CR42","doi-asserted-by":"publisher","unstructured":"Mocking, T. R. et al. Flow cytometry data from: computational measurable residual disease assessment in acute myeloid leukemia using mixture models. Zenodo. https:\/\/doi.org\/10.5281\/zenodo.11046402 (2024).","DOI":"10.5281\/zenodo.11046402"},{"key":"700_CR43","doi-asserted-by":"publisher","unstructured":"Mocking, T. R. et al. Code from: computational measurable residual disease assessment in acute myeloid leukemia using mixture models. Zenodo. https:\/\/doi.org\/10.5281\/zenodo.13474900 (2024).","DOI":"10.5281\/zenodo.13474900"}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-024-00700-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-024-00700-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-024-00700-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T03:07:04Z","timestamp":1735614424000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-024-00700-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["700"],"URL":"https:\/\/doi.org\/10.1038\/s43856-024-00700-x","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,19]]},"assertion":[{"value":"5 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"271"}}